A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Opicinumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms AFFINITY
- Sponsors Biogen
- 05 Oct 2017 Status changed from not yet recruiting to recruiting.
- 29 Sep 2017 Planned End Date changed from 13 Apr 2021 to 8 Dec 2020.
- 29 Sep 2017 Planned primary completion date changed from 20 Dec 2020 to 15 Sep 2020.